#USA #New York #Class Action #The Gross Law Firm #Pacira BioSciences

Attention Pacira BioSciences (PCRX) Shareholders

In a significant turn of events, shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX) are advised to engage The Gross Law Firm following a distressing decline in share prices resulting from a troubling patent infringement lawsuit. On February 27, 2025, The Gross Law Firm released a crucial notice aimed at affected investors, highlighting pertinent details that could impact their financial interests.

Background of the Case

The firm's announcement pertains to the aftermath of a court ruling regarding one of Pacira's key patents. On August 9, 2024, the court determined that the U.S. Patent No. 11,033,495, which is central to Pacira's main revenue-generating product, Exparel, was invalid. This patent accounts for a staggering 80% of the company’s revenue, raising immediate concerns about the company’s future profits and market position.

As a result of this ruling, Pacira's stock plummeted from $22.36 to $11.70 in a single day—a catastrophic loss of over 47%. Analysts have voiced their concerns that the invalidation of this patent could lead to more generic competitors entering the market, escalating litigation costs, and potentially harming the company's overall business viability.

Class Action Details

The Gross Law Firm is currently inviting shareholders who purchased shares of PCRX during the defined class period from August 2, 2023, to August 8, 2024, to participate in a class action lawsuit. It is important for shareholders to understand that becoming a lead plaintiff is not a requirement for participating in any recovery resulting from this case.

The deadline for potential lead plaintiffs to register is March 14, 2025, and The Gross Law Firm has established a user-friendly process for shareholders to submit their information to ensure they receive updates on the lawsuit's progress. Notably, there are no fees associated with being part of the class action, which reassures investors against any financial risk involved in participating.

Next Steps for Affected Shareholders

For those shareholders impacted by the rapid decline in stock prices, registering with The Gross Law Firm is a crucial step. Doing so not only provides access to vital updates about the case but also allows the firm to monitor the situation closely on behalf of the shareholders. The straightforward registration process ensures that all interested parties can stay informed as the lawsuit unfolds.

Reach Out to The Gross Law Firm

The Gross Law Firm is nationally recognized for advocating on behalf of investors who have been misled or harmed by corporate practices. Their commitment to investor rights and ethical business standards is reflected in their ongoing efforts to address issues of deceit and fraud in the financial markets.

To register, visit The Gross Law Firm’s registration page and ensure that your voice as a shareholder is heard.

The firm’s office can be reached at:

• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

Staying proactive is essential in the current financial climate, and acting swiftly can aid in protecting your investment.

Conclusion

The recent ruling against Pacira BioSciences represents a noteworthy case within the biotech sector, and affected shareholders must stay informed and take necessary actions. With significant financial implications at stake, proactive engagement with legal experts can offer investors a chance to recover losses and navigate the tumultuous market landscape effectively. Engage with The Gross Law Firm today to safeguard your interests before the opportunity passes.